The short interest in Apple (NASDAQ:AAPL) was steady in the period that ended on September 30 at 16 million shares.The bet being made against RIM (NASDAQ:RIMM) rose 13% to 13% to 19.2 million. The shares short in other major techs stocks dropped.
Shares short in Broadcom (NASDAQ:BRCD) dropped 14% to 19.1 million. Shares short in Juniper (NADSAQ:JNPR) dropped 11% to 36.8 million. The short interest in Symantec (NASDAQ:SYMC) dropped 8% to 12.9 million shares. Read More
Updated throughout the day.
Updated at 4.24 PM EST: Xyratex (NASDAQ:XRTX) is up 14% today, another tech stock in the buyout rumor mill. (Barron’s)
Updated at 2.12 PM EST: Euro Tech Holdings (CLWT) is up 40% on two million shares traded, about twent times it normal volume, on rumors that Chinese water companies will report better than expected sales for the last quarter (various)
Updated at 2.05 PM: Cell Therapeutics (NASDAQ:CTIC) continues to drop sharply down another 5% today on rumors of poor upcoming financial results or trouble with a drug trial (various)
Updated at 1.50 PM EST: Hedge fund Little Bear Investments, a noteholder in CIT (NYSE:CIT), is tying to get a group of bondholders to lobby for a larger equity stake in the commercial lender’s debt restructuring. (The Deal)
Updated at 1.35 PM EST: Microsoft (NASDAQ:MSFT) has cut its legal budget by 15% (LegalWeek)
Updated at 1.25 EST: Speculation has come up again that Brocade (NASDAQ:BRCD) will be sold to Hewlett-Packard (NYSE:HPQ). (Barron’s)
Update at 12:45 PM EST: NVIDIA Corporation (NASDAQ: NVDA) is currently halting graphic chipset production on compatibility innew Intel (INTC) newest microprocessors because of licensing disput. (WSJ)
A review of Citigroup (NYSE:C) management by consultant Egon Zehnder suggested that the chief administrative officer and vice chairman should go (CNBC)
Anadarko Petroleum (NYSE:ACP) and Tullow Oil are likely to be acquisition targets by larger oil companies. (The Deal)
Apple (NASDAQ:AAPL) may open as many as 1,000 retail stores in the next three years (MarketWatch)
Google’s (NASDAQ:GOOG) Android operating system will overtake the Apple iPhone in handset market share by 2012 (Apple Insider).
Twitter is talking to Microsoft (NASDAQ:MSFT) and Google about selling them data on the activity of its users (AllThingsD)
Douglas A. McIntyre
Updates throughout the day.
Update 2.40 PM EST: Biotech Cell Therapeutics (CTIC) is getting crushed, down 13% to $.95 on over 46 million shares. Rumors of insider selling, troubles with OPAXIO cancer, and possible dilution from possible raising of capital (various)
Update 1.50 PM EST: Cult stock Diedrich Coffee (DDRX) down 7% on heavy volume based on rumors shorts are aggressively moving into the shares which are up almost 7,000% this year. (various)
Update 12.05 PM EST: After announcing a delay in the 747-8 Freighter and a $1 billion charge, Boeing (BA) CEO Jim McNerney’s job could be on the line (DJ Newswires).
Update 9.55 AM EST: Exxon Mobil (XOM) has agreed to buy Kosmos Energy’s stake in the Jubilee field in Ghana. (CNBC)
Kaufman industry sources say BMC, Citrix (CTXS), VMware (VMW), Symantec (SYMC), and CA (CA) are potential tech buyout targets. (Briefing.com)
Yahoo! (YHOO) might sell Zimbra, Hot Jobs, and Yahoo! Small Business. (SAI)
Rogers Communications will lose its exclusive deal for selling the Apple (AAPL) iPhone in Canada. Telus and Bell Canada will get franchises (Globe and Mail).
Pay czar Kenneth Feinberg will cut cash compensation for executives at a number of firms which may include AIG (AIG), Citigroup (C), and Bank of America (BAC) (WSJ)
Citigroup’s Pandit could be the next big bank CEO pushed out the door. (The Deal)
Lawyers working on Viacom’s (VIA) lawsuit against Google’s (GOOG) YouTube have found e-mails uncovered evidence that “employees of the video site were among those who uploaded unauthorized content to YouTube.” (CNET)
Douglas A. McIntyre
Cell Therapeutics, Inc. (NASDAQ: CTIC) has announced what may be a large breakthrough in the fight against cancer. This is a combined test rather than as a standalone treatment, but the result may be a huge step in cancer of the lower esophagus. As many of the ties of one cancer are made to others, you can imagine that the hope might be that this would have other possibilities as well in the fight against other or related cancers.
The company said that a study from Brown University to be presented in the proffered oral session at the Annual Meeting of the International Society of Gastrointestinal Oncology in Philadelphia patients with cancer of the lower esophagus showed a high rate of complete remission when given OPAXIO(TM). This is paclitaxel poliglumex, which is a biologically enhanced paclitaxel. This result was shown when OPAXIO was administered in combination with standard cisplatin and concurrent radiation.
Cell Therapeutics noted that the phase II study was led by Dr. Safran and enrolled 40 patients with pathologically-confirmed and locally-advanced adenocarcinoma or squamous cell carcinoma of the esophagus or gastro-esophageal junction with no evidence of distant metastasis. These 40 patients received weekly paclitaxel poliglumex and cisplatin for six weeks with concurrent radiation. Of the first 28 patients undergoing surgery, all 8 of the 28 with adenocarcinoma have achieved a pathologic complete remission. No patients required a feeding tube, which differs from historical studies using the standard regimen where the large majority of patients require a feeding tube.
The company said that Paclitaxel poliglumex’s selective radiation enhancement preclinical profile is being validated by the high rates of pathologic complete remission, and by low rates of severe regional side effects observed in this phase 2 study. It also noted that the results justify proceeding to a randomized, controlled trial to definitively prove the clinical benefit observed. It also plans to speak with the FDA regarding a potential phase III registration strategy for this indication. Further noted is that this would ‘be the first registration study for a radiation sensitizing agent in this indication.’
As this is a $1.23 stock and has a 52-week trading range of $0.05 to $2.28, you can imagine there will be a lot of trading around this small cap name on Thursday. Additional results and safety data is offered below.
Read More
These are this Wednesday morning’s top pre-market day trader alert and active trader alert stocks moving on unusual trading volume. We have a link through to more color and analysis on price and volume over at VSInvestor.com on each stock:
AEterna Zentaris Inc. (NASDAQ: AEZS) and Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) are both ramping higher an FDA orphan-drug designation news.
Agco Corp. (AGCO) is trading lower by 7% on lower guidance.
American Capital Ltd. (NASDAQ: ACAS) is surging almost 20% after Corning Incorporated (NYSE: GLW) paid $400 million in cash for shares of another portfolio company.
Cell Therapeutics, Inc. (NASDAQ: CTIC) is up 5% on very active volume on more pixantrone for non-Hodgkin’s lymphoma news, but this is on positive data.
Citigroup, Inc. (NYSE: C) is up again on strong volume… we have color on prior day’s price levels here for inference.
Flextronics International Ltd. (NASDAQ: FLEX) is surging by almost 9% this morning after a Jim Cramer tout last night.. we are watching EMS rivals like Celestica Inc. (NYSE: CLS), Sanmina-SCI Corp. (NASDAQ: SANM) and Jabil Circuit Inc. (NYSE: JBL) on this.
Omniture, Inc. (NASDAQ: OMTR) is the biggest volume stock in the pre-market at NASDAQ after getting acquired by Adobe Systems, Inc. (NASDAQ: ADBE).
You can join our open email distribution list which goes out several times per week for top analyst upgrades and downgrades, top day trader alerts, IPO’s, key secondary offerings, guru investor data on Buffett and others, mergers, and more.
JON C. OGG
SEPTEMBER 16, 2009
We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend. This is broken down in drug and biotech companies with share values, ranges, and recent developments for the following drug and biotech companies: Abraxis BioScience, Inc. (NASDAQ:ABII), AEterna Zentaris Inc. (NASDAQ: AEZS), Allos Therapeutics, Inc. (NASDAQ: ALTH), Amgen Inc. (NASDAQ: AMGN), A.P. Pharma, Inc. (Nasdaq: APPA), Arqule Inc. (NASDAQ: ARQL), Bristol-Myers Squibb (NYSE: BMY), Celldex Therapeutics (NASDAQ: CLDX), Celgene Corporation (NASDAQ: CELG), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), Micromet, Inc. (NASDAQ: MITI), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Rosetta Genomics (NASDAQ:ROSG), Synta Pharmaceuticals (NASDAQ: SNTA), Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), ZIOPHARM Oncology (NASDAQ: ZIOP), and ZymoGenetics, Inc. (NASDAQ: ZGEN).
The full presentation can be seen at BioHealthInvestor.com.
JON C. OGG
May 27, 2009
We are just about to get the first round of abstracts from companies presenting data at this year’s American Society of Clinical Oncology meeting for 2009. At BioHealthInvestor.com we compiled a brief summary for companies such as Abraxis BioScience, Inc. (NASDAQ:ABII), Allos Therapeutics, Inc. (NASDAQ: ALTH), Arqule Inc. (NASDAQ: ARQL), Celldex Therapeutics (NASDAQ: CLDX), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Synta Pharmaceuticals (NASDAQ: SNTA), and ZIOPHARM Oncology (NASDAQ: ZIOP).
You can see that full pre-report here at BiohealthInvestor.com. As always be advised that there may be new sets of data released between now and the actual meeting from May 29 to June 2, 2009 in Orlando, Florida.
We are still seeing many auditor notes containing a “going concern” doubt about companies and their ability to continue operations without added funding or business changes. Last week,we outlined many household names that had received going concern notes. Even American International Group, Inc. (NYSE: AIG) has a going concern note in the International Lease Finance Corporation unit’s annual report. This week we have already seen another wave of these from Cell Therapeutics, Inc. (NASDAQ: CTIC), Coachmen Industries Inc. (NYSE: COA), Empire Resorts Inc. (NASDAQ: NYNY), Triad Guaranty Inc. (NASDAQ: TGIC).
Read More
Spectrum Brands (SPC) No big news. Still falling after posting loss. Down to $1.67 from 52-week high of $6.20.
Prologis (PLD) Company recently increased presence in Mexico, but no other news. Drifts off to $42.50 from 52-week high of $73.35.
Cell Therapeutics (CTIC) Moving down several days after poor quarter. Hits bottom at $.25 off from 52-week high of $4.
Telik (TELK) No news, just dead air. Sells off to $.64 from 52-week high of $4.96.
Douglas A. McIntyre
Cell Therapeutics (NASDAQ: CTIC) has filed an open mixed securities shelf registration for up to $150 million. This will allow it to sell debt securities, common stock, preferred stock, and warrants.
Last Tuesday, the company announced progress in beginning Phase III testing for its non-Hodgkin’s lymphoma treatment. Friday, the company filed its annual report.
Shares have showed no reaction to the filing, with a 0% change, sitting at $0.66. The 52-week range is $0.47 to $7.56 and its current market cap is only $62.5 million.
Rachel Lopez
March 31, 2008
Fremont General (FMT) Fear of Chapter 11 grows. Falls to $.39 from 52-week high of $13.80.
Verasun Energy (VSE) High commodity prices kill ethanol stocks. Down to $7.76 from 52-week high of $21.47.
Hertz Global Holdings (HTZ) Low travel, high fuel costs. Sells down to $10.59 from 52=week high of $27.20.
McClatchy (MNI) Picture for newspapers gets worse by the month. Drops to $9 from 52-week high of $36.97.
Citigroup (C) Concern that bank will need more money. Drops to $21.23 from 52-week high of $55.55.
Sprint (S) Market still worried that competition is taking subscribers. Sells off to to $6.70 from 52-week high of $23.42.
Cell Therapeutics (CTIC) Company issues senior notes and pushes debt sky-high. Sells down to $.67 from 52-week high of $7.56.
Tessera Technologies (TRSA) Patent lawsuit stayed by ITC. Shares down to $11.11 from 52-week high of $46.43.
Finisar (FNSR) Misses quarterly numbers. Drops to $1.15 from 52-week high of $4.21.
Douglas A. McIntyre
Stock Tickers: AVR, BCRX, CACH, CHCI, COLY, CTIC, FSII, HOV, HR, INFS, LEG, MTH, PEIX, RSYS, SCSS, SEPR, SNY, STAA, USBE, UTSI, VSE, YSI
Once again, many many more losers…..This list is larger than most of recent note. There is just about any given day where there are fresh 52-week lows:
Aventine Renewable (AVR)…-3.9% to $14.09; $14.60 prior low. Watch the renewable energy names as they are plentiful on 52-week lows.
BioCryst Pharma (BCRX)…-3.3% at $6.92; prior 52-week low $7.13; follow-on weakness from Peramivir Monday.
Cache (CACH)…-2.7% to $13.92; not lowest intraday but low close.
Comstock Homebuilders (CHCI)…-4.4% to $2.83; another stinking homebuilder.
Coley Pharma (COLY)….-59% to $3.46; $8.00 prior lows; intra-day implosion as Pfizer ditches its cancer drug.
Cell Therapeutics (CTIC)…-9.4% to $3.09; prior 52-week low was $3.38.
FSI International (FSII)….-13% to $3.43; $3.91 was prior low; weak guidance; hedge fund pressures CEo.
Hovnanian Enterprises (HOV)…-3% to $19.08; prior 52-week low $19.53; another stinking homebuilder.
Healthcare Realty (HR) -2.2% to $28.34; prior 52-week low was $28.57; this one goes lower and lower each week it feels like.
InFocus (INFS) -4% to $2.33; follow-on weakness after CFO quit; stock imploding….
Leggett & Platt (LEG)…-0.7% to $21.92; not tru 52-week low but low close; continued weakness after estimates cut from housing.
Meritage Homes (MTH)..-1.5% to $28.75; another stinking homebuilder.
Pacific Ethanol (PEIX)…-2.35 to $12.35; lowest close of late; and we thought ethanol was king…..
Radisys (RSYS)…-3.8% to $12.80; not true low but low close and hit intraday lows; no news today.
Select Comfort (SCSS)…-2.1% to $16.03; prior low $16.09; weak housing must mean weak bed sales; maybe hamocs are the new rage?
Sepracor (SEPR)…-2.5% to $43.67; prior 52-week low $43.84; insiders exercising stock options this week; P/E ratio drifting lower and lower; now down 33% from highs.
Sanofi-Aventis (SNY)…-1.8% to $40.84; prior low $41.09; drug woes continue; worries they’ll dilute to buy Bristol-Myers.
Staar Surgical (STAA)…-2.85% to $4.09; $4.14 prior 52-week lows; no news, but not a ’staar’ after all.
US Bioenergy (USBE)…-2.6% to $10.67; $10.78 prior low; busted IPO looks like worse getting even worse.
UTSarcom (UTSI)…-3.8% to $5.28; $5.43 was prior 52-week low; down more than 50% in last year; the beatings will continue until leadership improves AND until they actually report and open the books.
VeraSun (VSE)…-4.7% to $13.08; $13.69 was prior 52-week low; ethanol slide continues.
u_Store-It Trust (YSI)…-2.9% to $16.97; $17.05 was prior intra-day low; no news, but they obviously aren’t storing enough.
Jon C. Ogg
June 20, 2007
Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in any of the companies he covers.
Stock Tickers: AZN, BCRX, EHTH, CTIC, HW, NRMX, SBUX, WFMI, DUK
It’s no secret we had the makings of a crummy week, but the market managed to turn itself back around after a fairly week open. Regardles of a bull market or any market, there are still stocks hitting 52-week lows:
AstraZeneca (AZN) ADR’s put in lows, two days after the CFO left to join Goldman Sachs.
BioCryst (BCRX) stays weak, apparently the near-term bounce turned back into a pounce.
Cell Therapeutics (CTIC) managed to keep its post-ASCO slide going.
eHealth, Inc (EHTH) put in the lowest close since its October IPO.
Headwaters (HW) just keeps slipping and looks uglier daily, and has been oin a crash course for about 6 weeks..
Neurochem (NRMX) closed down another 10% after the poor drug outlook yesterday.
Starbucks (SBUX) and Whole Foods (WFMI) were in the 52-week low gutter club earlier but got bailed out by the market offer. Duke Energy (DUK) also rode most of the day on new adjusted lows before an end of day recovery, although these might not be ultimate 52-week lows on an adjusted basis.
Jon C. Ogg
June 8, 2007
Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.
| Today’s top tickerspy Indexes | |
| Coffee Stocks | +16.3% |
| Hotel Stocks | +9.0% |
| 2009 IPOs | +8.2% |
| Education Stocks | +4.7% |
| Coal Stocks | +4.4% |
 | |
| |
RSS Updates
Email Updates
